Search Videos and More
Document
Tip Sheet: Laboratory Monitoring for Patients on Oral Chemotherapy or Oral Targeted Therapies
The Breast Oncology Center developed this reference for providers on lab monitoring for patients on oral chemotherapy or oral targeted therapies in November 2025.
Course
3rd Annual Lynch Syndrome Scientific Symposium
The 3rd Annual Lynch Syndrome Scientific Symposium will be held on Monday, April 13 at Hotel Commonwealth in Boston, MA. This symposium is dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome. We will be accepting abstracts on Lynch syndrome research and relevant case reports. The deadline to submit an abstract is February 16, 2026 at 11:59PM EST.
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: SABCS 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at SABCS 2025 in San Antonio, Texas providing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data mean, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber Research News 12.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.
News
Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
dolescent and young adult breast cancer survivors who used a novel mobile health (mHealth) intervention to self-manage post-treatment symptoms and concerns were able to improve their quality of life and reduce the burden of common symptoms compared to patients who received usual care, according to results from a new clinical trial being reported at the 2025 San Antonio Breast Cancer Symposium (SABCS).
News
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.